Arrowstreet Capital’s AnaptysBio ANAB Stock Holding History

Arrowstreet Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33M	Sell	488,651 -3,469	-0.7%	-$210K	0.01%	705
2026 Q1	$27.3M	Sell	492,120 -67,624	-12%	-$3.64M	0.01%	664
2025 Q4	$27.1M	Buy	559,744 +189,286	+51%	+$7.38M	0.02%	651
2025 Q3	$11.3M	Buy	370,458 +219,648	+146%	+$5.04M	0.01%	919
2025 Q2	$3.35M	Buy	+150,810	New	+$3.16M	﹤0.01%	1301
2022 Q2	–	Sell	-9,862	Closed	-$244K	–	1217
2022 Q1	$244K	Sell	9,862 -62,639	-86%	-$1.9M	﹤0.01%	1103
2021 Q4	$2.52M	Buy	+72,501	New	+$2.3M	﹤0.01%	962
2021 Q1	–	Sell	-143,415	Closed	-$3.08M	–	2220
2020 Q4	$3.08M	Sell	143,415 -12,900	-8%	-$313K	﹤0.01%	1428
2020 Q3	$2.31M	Buy	156,315 +63,532	+68%	+$1.15M	﹤0.01%	1499
2020 Q2	$2.07M	Buy	+92,783	New	+$1.7M	﹤0.01%	1463

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Arrowstreet Capital's ANAB Position: Q2 2026 in Review

Arrowstreet Capital reduced its AnaptysBio (ANAB) stake by 0.7% in Q2 2026, selling an estimated $210K and leaving 488,651 shares worth $33M. The position accounts for 0.01% of the portfolio, ranked #705.

Arrowstreet Capital first reported a position in ANAB in Q2 2020 and has held it in 10 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Arrowstreet Capital held 488,651 shares of AnaptysBio worth $33M as of Q2 2026.
Arrowstreet Capital sold 3,469 AnaptysBio shares in Q2 2026, an estimated $210K.
AnaptysBio made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #705 holding.
Arrowstreet Capital first reported a position in AnaptysBio in Q2 2020 and has held it in 10 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.